A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1 - Full Text View

A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1

This study is ongoing, but not recruiting participants.

Sponsored by:	National Institute on Drug Abuse (NIDA)
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00033124

Purpose

The purpose of this study is to examine behavioral treatment for methamphetamine dependence.

Condition	Intervention	Phase
Substance-Related Disorders	Behavioral: Behavior Therapy	Phase II

MedlinePlus related topics:

Methamphetamine

Drug Information available for:

Methamphetamine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Behavioral Trial for the Treatment of Methamphetamine Dependence

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Withdrawal symptoms
New Use algorithm

Estimated Enrollment:	50
Study Start Date:	July 2001
Estimated Study Completion Date:	June 2002

Detailed Description:

To characterize meth. withdrawal symptoms using a multidimensional withdrawal questionnaire; to field test and investigate the effect of using an algorithm developed for discriminating between new use and residual carry-over of meth metabolites in urine and to evaluate the treatment response of meth. users to participation in the thrice weekly psychosocial protocol to be used as a "platform" in future pharmacotherapy trials.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or Female at least 18 yrs of age; DSM-4 diagnosis of methamphetamine (METH) dependence; be willing to comply with study procedures; verbalize understanding of consent and provide written consent and willingness to complete study procedures; be seeking treatment for METH dependence.

Exclusion Criteria:

Additional criteria available during screening at the site.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033124

Locations


United States, California
	Matrix Institute on Addictions
	Costa Mesa, California, United States, 92627
	South Bay Treatment Center
	Chula Vista, California, United States, 91911

United States, Hawaii
	John A. Burns School of Medicine
	Honolulu, Hawaii, United States, 96813

United States, Iowa
	Powell Chemical Dependency Center
	Des Moines, Iowa, United States, 50316

United States, Missouri
	Comprehensive Mental Health Services, Inc
	Independence, Missouri, United States, 64052

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Richard Rawson, Ph.D.	National Institute on Drug Abuse (NIDA)

More Information

Study ID Numbers:	NIDA-CTO-0009-1
First Received:	April 5, 2002
Last Updated:	February 8, 2007
ClinicalTrials.gov Identifier:	NCT00033124
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Methamphetamine

Dopamine

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Adrenergic Agents

Sympathomimetics

Adrenergic Uptake Inhibitors

Physiological Effects of Drugs

Central Nervous System Stimulants

Pharmacologic Actions

Autonomic Agents

Therapeutic Uses

Dopamine Agents

Peripheral Nervous System Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on November 30, 2008